MDPI and ACS Style
Li, H.-S.; Wang, S.-Z.; Xu, H.-Y.; Yan, X.; Zhang, J.-Y.; Lei, S.-Y.; Li, T.; Hao, X.-Z.; Zhang, T.; Yang, G.-J.;
et al. Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study). Cancers 2022, 14, 5307.
https://doi.org/10.3390/cancers14215307
AMA Style
Li H-S, Wang S-Z, Xu H-Y, Yan X, Zhang J-Y, Lei S-Y, Li T, Hao X-Z, Zhang T, Yang G-J,
et al. Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study). Cancers. 2022; 14(21):5307.
https://doi.org/10.3390/cancers14215307
Chicago/Turabian Style
Li, Hong-Shuai, Shou-Zheng Wang, Hai-Yan Xu, Xiang Yan, Jin-Yao Zhang, Si-Yu Lei, Teng Li, Xue-Zhi Hao, Tao Zhang, Guang-Jian Yang,
and et al. 2022. "Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study)" Cancers 14, no. 21: 5307.
https://doi.org/10.3390/cancers14215307